The use of pulmonary clearance medications in the acutely ill patient

Michael F. Papacostas, Peter Luckett, Susan Hupp

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: Retention of airway secretions occurs in disease, leading to airway plugging, atelectasis, and worsened respiratory mechanics, making airway clearance an important therapeutic target. Areas covered: Many medications designed to enhance clearance of airway secretions are available. We will review the medications available to enhance airway clearance, their mechanisms of action, and the evidence available for their use in acutely ill patients. Expert commentary: In the cystic fibrosis (CF) population, beneficial effects have been shown in pulmonary function with the use of some of these agents. In the non-CF population, there is limited evidence regarding these medications. While some studies have found benefit, the quality of evidence is low, making it difficult to draw conclusions. While certain patients may derive benefit, the general use of these medications in acutely ill patients without CF cannot be recommended at this time.

Original languageEnglish (US)
Pages (from-to)815-826
Number of pages12
JournalExpert Review of Respiratory Medicine
Volume11
Issue number10
DOIs
StatePublished - Oct 3 2017

Fingerprint

Cystic Fibrosis
Lung
Respiratory Mechanics
Pulmonary Atelectasis
Population
Fibrosis
Therapeutics

Keywords

  • Airway secretions
  • hypertonic saline
  • mucolytics
  • mucus
  • pulmonary clearance
  • sputum

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health

Cite this

The use of pulmonary clearance medications in the acutely ill patient. / Papacostas, Michael F.; Luckett, Peter; Hupp, Susan.

In: Expert Review of Respiratory Medicine, Vol. 11, No. 10, 03.10.2017, p. 815-826.

Research output: Contribution to journalReview article

Papacostas, Michael F. ; Luckett, Peter ; Hupp, Susan. / The use of pulmonary clearance medications in the acutely ill patient. In: Expert Review of Respiratory Medicine. 2017 ; Vol. 11, No. 10. pp. 815-826.
@article{2a2926ab3e2e4076a3c74d05783bc5f4,
title = "The use of pulmonary clearance medications in the acutely ill patient",
abstract = "Introduction: Retention of airway secretions occurs in disease, leading to airway plugging, atelectasis, and worsened respiratory mechanics, making airway clearance an important therapeutic target. Areas covered: Many medications designed to enhance clearance of airway secretions are available. We will review the medications available to enhance airway clearance, their mechanisms of action, and the evidence available for their use in acutely ill patients. Expert commentary: In the cystic fibrosis (CF) population, beneficial effects have been shown in pulmonary function with the use of some of these agents. In the non-CF population, there is limited evidence regarding these medications. While some studies have found benefit, the quality of evidence is low, making it difficult to draw conclusions. While certain patients may derive benefit, the general use of these medications in acutely ill patients without CF cannot be recommended at this time.",
keywords = "Airway secretions, hypertonic saline, mucolytics, mucus, pulmonary clearance, sputum",
author = "Papacostas, {Michael F.} and Peter Luckett and Susan Hupp",
year = "2017",
month = "10",
day = "3",
doi = "10.1080/17476348.2017.1358089",
language = "English (US)",
volume = "11",
pages = "815--826",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - The use of pulmonary clearance medications in the acutely ill patient

AU - Papacostas, Michael F.

AU - Luckett, Peter

AU - Hupp, Susan

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Introduction: Retention of airway secretions occurs in disease, leading to airway plugging, atelectasis, and worsened respiratory mechanics, making airway clearance an important therapeutic target. Areas covered: Many medications designed to enhance clearance of airway secretions are available. We will review the medications available to enhance airway clearance, their mechanisms of action, and the evidence available for their use in acutely ill patients. Expert commentary: In the cystic fibrosis (CF) population, beneficial effects have been shown in pulmonary function with the use of some of these agents. In the non-CF population, there is limited evidence regarding these medications. While some studies have found benefit, the quality of evidence is low, making it difficult to draw conclusions. While certain patients may derive benefit, the general use of these medications in acutely ill patients without CF cannot be recommended at this time.

AB - Introduction: Retention of airway secretions occurs in disease, leading to airway plugging, atelectasis, and worsened respiratory mechanics, making airway clearance an important therapeutic target. Areas covered: Many medications designed to enhance clearance of airway secretions are available. We will review the medications available to enhance airway clearance, their mechanisms of action, and the evidence available for their use in acutely ill patients. Expert commentary: In the cystic fibrosis (CF) population, beneficial effects have been shown in pulmonary function with the use of some of these agents. In the non-CF population, there is limited evidence regarding these medications. While some studies have found benefit, the quality of evidence is low, making it difficult to draw conclusions. While certain patients may derive benefit, the general use of these medications in acutely ill patients without CF cannot be recommended at this time.

KW - Airway secretions

KW - hypertonic saline

KW - mucolytics

KW - mucus

KW - pulmonary clearance

KW - sputum

UR - http://www.scopus.com/inward/record.url?scp=85029499438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029499438&partnerID=8YFLogxK

U2 - 10.1080/17476348.2017.1358089

DO - 10.1080/17476348.2017.1358089

M3 - Review article

C2 - 28780895

AN - SCOPUS:85029499438

VL - 11

SP - 815

EP - 826

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 10

ER -